GlassScriptPhysician profile
Makayla Blain
NPI 1821606500
$3,881.30
in general payments reported to CMS, 2019-2025
24 companies · $818 in 2025
The $818 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $623 · 2022: $443 · 2023: $954 · 2024: $1,042 · 2025: $818.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,815.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,814.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,106.17 | 2021-2025 | |
| Collegium Pharmaceutical, INC. | $324.87 | 2021-2025 | Belbuca, Xtampza |
| Boston Scientific Corporation | $319.72 | 2023-2024 | Wavewriter Alpha Prime 16, Artisan |
| Spinal Simplicity, LLC | $309.31 | 2023-2024 | Ha Minuteman G3-R |
| Pfizer INC. | $221.83 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $174.90 | 2021-2023 | Relistor |
| Nalu Medical, INC. | $148.83 | 2025 | Nalu Neurostimulation System |
| Curonix LLC | $147.46 | 2023 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Stimwave Technologies Incorporated | $141.77 | 2021 | |
| Globus Medical, INC. | $139.80 | 2025 | Omnia |
| Biohaven Pharmaceuticals, INC. | $126.42 | 2021 | |
| Scilex Pharmaceuticals INC. | $113.34 | 2022-2023 | Ztlido |
| Antares Pharma, INC. | $101.07 | 2022-2024 | Xyosted |
| Lilly USA, LLC | $94.10 | 2021-2023 | Emgality, Reyvow |
| Lundbeck LLC | $80.19 | 2024-2025 | Vyepti |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $77.29 | 2025 | |
| Amgen INC. | $54.80 | 2021-2022 | |
| Axsome Therapeutics, INC. | $43.71 | 2025 | Symbravo |
| Biohaven Pharmaceutical Holding Company LTD. | $42.26 | 2022 | |
| Halozyme INC | $36.13 | 2023 | |
| Biogen, INC. | $20.94 | 2024 | Skyclarys |
| Bioventus LLC | $20.90 | 2022 | |
| Merck Sharp & Dohme LLC | $18.09 | 2022 | |
| Biodelivery Sciences International, INC. | $17.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Makayla Blain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.